Pharmaceutical company Elan and its partner Biogen have announced that their multiple sclerosis treatment Tysabri is now available again in the US.
This follows approval from the US Food & Drug Administration, which backed the drug's return in June, subject to a number of conditions.
The companies also say Tysabri has been introduced in several countries in Europe following recent approval from the European Commission.
The drug had been withdrawn in February 2005 after the deaths of two patients involved in trials of the drug from a rare brain disease, PML.
